Metoprolol Succinate Aurobindo

Metoprolol Tartrate, the active ingredient in Metoprolol Succinate Aurobindo, is a beta‑blocker presented as an oral tablet for oral use. It is used to manage hypertension, angina, myocardial infarction, heart failure, and certain cardiac arrhythmias in adult patients.

GNH USA supplies Metoprolol Succinate Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Tartrate is indicated for several cardiovascular conditions that involve elevated blood pressure or cardiac workload. - Hypertension: reduces systolic and diastolic blood pressure, lowering cardiovascular risk. - Angina pectoris: decreases myocardial oxygen demand, relieving chest‑pain episodes. - Myocardial infarction: improves survival by reducing cardiac workload after an acute event. - Heart failure: enhances left ventricular function and reduces hospitalization rates. - Cardiac arrhythmias: controls heart rate in atrial fibrillation and other supraventricular tachyarrhythmias.

Metoprolol Tartrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: feeling of tiredness or reduced energy. - Dizziness: light‑headedness, especially when standing quickly. - Bradycardia: slower than normal heart rate. - Gastrointestinal discomfort: nausea, abdominal pain or constipation.

Serious or Rare Side Effects: - Severe bronchospasm: difficulty breathing, particularly in patients with asthma or COPD. - Heart block: abnormal electrical conduction that may require a pacemaker. - Hypotension: markedly low blood pressure leading to fainting or shock.

When prescribing Metoprolol Tartrate, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiac function: evaluate heart rate and blood pressure before initiation. - Review respiratory history: avoid in patients with active bronchospastic disease. - Monitor for depression: beta‑blockers can exacerbate mood disorders. - Adjust in renal/hepatic impairment: dose may need modification in reduced clearance. - Caution with abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metoprolol Tartrate interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): risk of severe heart block and reduced cardiac output. - Clonidine withdrawal: abrupt cessation may cause rebound hypertension if beta‑blocker is continued.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may mask hypoglycemia symptoms. - NSAIDs (ibuprofen, naproxen): can diminish antihypertensive effect. - Antidepressants (SSRIs, tricyclics): may increase plasma levels of metoprolol. - Digoxin: enhanced risk of bradyarrhythmias.